Revenue Update on Antares Pharma Inc(NASDAQ:ATRS)

Antares Pharma Inc(NASDAQ:ATRS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $12.23M. Analysts estimated a revenue of $11.00M. Earnings per share were $-0.04. Analysts had estimated an EPS of $-0.04.

Antares Pharma Inc (ATRS) shares turned negative on Wednesdays trading session with the shares closing down -0.01 points or -0.92% at a volume of 4,01,191. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.1. The peak price level was also seen at $1.1 while the days lowest was $1.03. Finally the shares closed at $1.08. The 52-week high of the shares is $2.03 while the 52-week low is $0.67. According to the latest information available, the market cap of the company is $167 M.

Several Insider Transactions has been reported to the SEC. On Mar 23, 2016, Peter J Graham (SVP General Counsel, Secretary) purchased 20,000 shares at $0.77 per share price.Also, On Mar 22, 2016, Robert P Jr Roche (director) purchased 50,000 shares at $0.72 per share price.On Mar 21, 2016, Jacques Gonella (director) purchased 100,000 shares at $0.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Antares Pharma Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners pressure-assisted injectors with and without needles which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled single-use disposable injector called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Antares Pharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Antares Pharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.